Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

Core Viewpoint - Stryker has successfully acquired Inari Medical, enhancing its position in the venous thromboembolism (VTE) market and expanding its interventional endovascular portfolio [1][2]. Company Overview - Stryker is a global leader in medical technologies, offering innovative products and services in MedSurg, Neurotechnology, and Orthopaedics, impacting over 150 million patients annually [5]. Acquisition Details - The acquisition was completed on February 19, 2025, following a cash tender offer of $80.00 per share for Inari's outstanding shares, which resulted in approximately 81.69% of shares being validly tendered [3][4]. - Inari Medical's product portfolio includes the FlowTriever System and ClotTriever System, which are complementary to Stryker's existing Neurovascular business [2][4]. Market Impact - The acquisition positions Stryker to improve patient outcomes in the fast-growing VTE segment, leveraging Inari's innovative solutions for clot removal without thrombolytic drugs [1][2].